EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability—Brief Report

Michael T Patterson iD, Yingzheng Xu iD, Hannah Hillman iD, Victoria Osinski iD, Patricia R Schrank iD, Ainsley E Kennedy, Fanta Barrow iD, Alisha Zhu, Samuel Tollison, Sia Shekhar, Ingunn M Stromnes iD, Ilaria Tassi iD und 4 weitere

Arteriosclerosis, Thrombosis, and Vascular Biology · 2024-07 · 44 (7) · 1646-1657

DOI: 10.1161/atvbaha.124.320797 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024-07. Verfasst von Michael T Patterson und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immunology (M.T.P., Y.X., H.H., V.O., P.R.S., A.E.K., F.B., A.Z., S.T., S.S., I.M.S., X.S.R., B.A.B., J.W.W.), University of Minnesota, Mi…. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Receptors, Immunologic, Membrane Glycoproteins, Disease Models, Animal. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Trem2 (triggering receptor on myeloid cells 2), a surface lipid receptor, is expressed on foamy macrophages within atherosclerotic lesions and regulates cell survival, proliferation, and anti-inflammatory responses. Studies examining the role of Trem2 in atherosclerosis have shown that deletion of Trem2 leads to impaired foamy macrophage lipid uptake, proliferation, survival, and cholesterol efflux. Thus, we tested the hypothesis that administration of a Trem2 agonist antibody (AL002a) to atherogenic mice would enhance macrophage survival and decrease necrotic core formation to improve plaque stability. METHODS: To model a therapeutic intervention approach, atherosclerosis-prone mice (Ldlr [low-density lipoprotein receptor] −/− ) were fed a high-fat diet for 8 weeks, then transitioned to treatment with AL002a or isotype control for an additional 8 weeks while continuing on a high-fat diet. RESULTS: AL002a-treated mice had increased lesion size in both the aortic root and whole mount aorta, which correlated with an expansion of plaque macrophage area. This expansion was due to increased macrophage survival and proliferation in plaques. Importantly, plaques from AL002a-treated mice showed improved features of plaque stability, including smaller necrotic cores, increased fibrous caps, and greater collagen deposition. Single-cell RNA sequencing of whole aorta suspensions from isotype- and AL002a-treated atherosclerotic mice revealed that Trem2 agonism dramatically altered foamy macrophage transcriptome. This included upregulation of oxidative phosphorylation and increased expression of collagen genes. In vitro studies validated that Trem2 agonism with AL002a promoted foamy macrophage oxidized low-density lipoprotein uptake, survival, and cholesterol efflux. CONCLUSIONS: Trem2 agonism expands atherosclerotic plaque macrophages by promoting cell survival and proliferation but improves features of plaque stability by rewiring foamy macrophage function to enhance cholesterol efflux and collagen deposition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plaque, AtheroscleroticReceptors, ImmunologicMembrane GlycoproteinsDisease Models, AnimalAtherosclerosisFoam CellsMice, Inbred C57BLMice, KnockoutAnimalsMiceMaleReceptors, LDLCell ProliferationDiet, High-FatCell SurvivalNecrosisAortic Diseases

Stichwörter der Autor:innen

anti-inflammatory agentscell proliferationcholesterolcollagenmacrophages

Substanzen

Receptors, ImmunologicTrem2 protein, mouseMembrane GlycoproteinsReceptors, LDL

Autor:innen und Institutionen

  • Center for Immunology (M.T.P., Y.X., H.H., V.O., P.R.S., A.E.K., F.B., A.Z., S.T., S.S., I.M.S., X.S.R., B.A.B., J.W.W.), University of Minnesota, Minneapolis.
  • Department of Integrative Biology and Physiology (M.T.P., Y.X., H.H., P.R.S., A.E.K., F.B., A.Z., S.T., S.S., X.S.R., J.W.W.), University of Minnesota, Minneapolis.
  • Department of Pediatrics (V.O., B.A.B.), University of Minnesota, Minneapolis.
  • Department of Microbiology and Immunology (I.M.S.), University of Minnesota, Minneapolis.
  • Alector, Inc, South San Francisco, CA (I.T., D.W.).
  • Now with Deep Apple Therapeutics, South San Francisco, CA (I.T.).

ORCID-Profile: Michael T Patterson, Yingzheng Xu, Hannah Hillman, Victoria Osinski, Patricia R Schrank, Fanta Barrow, Ingunn M Stromnes, Ilaria Tassi, Xavier S Revelo, Bryce A Binstadt, Jesse W Williams

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Patterson, M. T., Xu, Y., Hillman, H., Osinski, V., Schrank, P. R., Kennedy, A. E., Barrow, F., Zhu, A., Tollison, S., Shekhar, S., Stromnes, I. M., Tassi, I., Wu, D., Revelo, X. S., Binstadt, B. A., & Williams, J. W. (2024). Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(7), 1646-1657. https://doi.org/10.1161/atvbaha.124.320797

Vancouver

Patterson MT, Xu Y, Hillman H, Osinski V, Schrank PR, Kennedy AE, et al. Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44(7):1646-1657. doi:10.1161/atvbaha.124.320797

BibTeX
@article{Patterson2024,
  author = {Patterson, Michael T and Xu, Yingzheng and Hillman, Hannah and Osinski, Victoria and Schrank, Patricia R and Kennedy, Ainsley E and Barrow, Fanta and Zhu, Alisha and Tollison, Samuel and Shekhar, Sia and Stromnes, Ingunn M and Tassi, Ilaria and Wu, Dick and Revelo, Xavier S and Binstadt, Bryce A and Williams, Jesse W},
  title = {Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability—Brief Report},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2024},
  volume = {44},
  number = {7},
  pages = {1646--1657},
  doi = {10.1161/atvbaha.124.320797}
}
Kostenlos starten →